^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

A128 - AXL Mediates Cetuximab Resistance Through Tyrosine 821 and Activation of c-Abl kinase in Head and Neck Cancer

Published date:
10/27/2019
Excerpt:
Advancing this line of investigation in vivo indicated that tumors overexpressing AXL were resistant to cetuximab whereas tumors harboring the Y821 mutation were sensitive.